Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia - PubMed (original) (raw)
. 1995 May 1;85(9):2546-52.
Affiliations
- PMID: 7727782
Free article
Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia
M Kawamura et al. Blood. 1995.
Free article
Abstract
We have investigated the alterations of p53 and ras genes including H-, K-, and N-ras genes in 22 acute lymphoblastic leukemia (ALL) cases and five cell lines carrying t(1;19) by use of polymerase chain reaction (PCR)-single-strand conformation polymorphism (SSCP) analysis and direct sequencing. The mutations of the p53 gene were found in 2 of 20 t(1;19)-ALL cases at diagnosis (10%), all of 4 cases at relapse (100%), and 4 of the 5 cell lines (80%). Four of the five patients who died had missense mutations at codons 49, 177, 179, and 248. In cases examined sequentially, one had the same point mutation at codon 179 at both diagnosis and relapse, and another had the same p53 gene mutation at codon 240 both in leukemic cells at relapse and in a cell line derived at that time. The other case had no mutation at diagnosis but had the mutation at codon 177 at relapse and cell lines derived from blast cells at diagnosis, suggesting that a small number of leukemic cells with the p53 gene mutation at diagnosis might have escaped PCR-SSCP analysis. In cell lines, SCMC-L9 had three point mutations in the p53 gene at codons 175, 248, and 358, whereas SCMC-L10 had frame shift at codons 209-211. One case had a rare polymorphism at codon 11. We found only one mutation of the N-ras gene that was a 2-bp substitution of GGT(Gly) to GTC(Val) at codon 13 among 22 t(1;19)-ALL cases and five cell lines. This case showed no mutation of the p53 gene and has had a good course. These results suggest that in t(1;19)-ALL, mutations of the p53 and ras genes are infrequent at diagnosis and that p53 gene alterations may be associated with relapse phase or progression of t(1;19)-ALL.
Similar articles
- Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.
Kawamura M, Ohnishi H, Guo SX, Sheng XM, Minegishi M, Hanada R, Horibe K, Hongo T, Kaneko Y, Bessho F, Yanagisawa M, Sekiya T, Hayashi Y. Kawamura M, et al. Leuk Res. 1999 Feb;23(2):115-26. doi: 10.1016/s0145-2126(98)00146-5. Leuk Res. 1999. PMID: 10071127 - A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
Sarkar FH, Valdivieso M, Borders J, Yao KL, Raval MM, Madan SK, Sreepathi P, Shimoyama R, Steiger Z, Visscher DW, et al. Sarkar FH, et al. Diagn Mol Pathol. 1995 Dec;4(4):266-73. doi: 10.1097/00019606-199512000-00007. Diagn Mol Pathol. 1995. PMID: 8634783 - RAS and FMS mutations following cytotoxic therapy for childhood acute lymphoblastic leukaemia.
Taylor C, McGlynn H, Carter G, Baker AH, Warren N, Ridge SA, Owen G, Thompson E, Thompson PW, Jacobs A, et al. Taylor C, et al. Leukemia. 1995 Mar;9(3):466-70. Leukemia. 1995. PMID: 7885045 - p53 mutations in larynx cancer.
Zhang LF, Hemminki K, Szyfter K, Szyfter W, Söderkvist P. Zhang LF, et al. Carcinogenesis. 1994 Dec;15(12):2949-51. doi: 10.1093/carcin/15.12.2949. Carcinogenesis. 1994. PMID: 8001261 Review. - The Role of Genetics and Synergistic Effect of Targeting Common Genetic Mutations in Acute Lymphoblastic Leukemia (ALL).
Pilehvari N, Katoueezadeh M, Hassanshahi G, Torabizadeh SA, Torabizadeh SM. Pilehvari N, et al. Mini Rev Med Chem. 2023;23(14):1435-1450. doi: 10.2174/1389557523666221207155909. Mini Rev Med Chem. 2023. PMID: 36503453 Review.
Cited by
- NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
Somazu S, Tanaka Y, Tamai M, Watanabe A, Kagami K, Abe M, Harama D, Shinohara T, Akahane K, Goi K, Sugita K, Moriyama T, Yang J, Goto H, Minegishi M, Iwamoto S, Takita J, Inukai T. Somazu S, et al. J Cell Mol Med. 2021 Nov;25(22):10521-10533. doi: 10.1111/jcmm.16981. Epub 2021 Oct 12. J Cell Mol Med. 2021. PMID: 34636169 Free PMC article. - Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia.
Oshima K, Zhao J, Pérez-Durán P, Brown JA, Patiño-Galindo JA, Chu T, Quinn A, Gunning T, Belver L, Ambesi-Impiombato A, Tosello V, Wang Z, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Balbin M, Nicolas C, Gastier-Foster JM, Devidas M, Loh ML, Paietta E, Tallman MS, Rowe JM, Litzow M, Minden MD, Meijerink J, Rabadan R, Ferrando A. Oshima K, et al. Nat Cancer. 2020 Nov;1(11):1113-1127. doi: 10.1038/s43018-020-00124-1. Epub 2020 Oct 19. Nat Cancer. 2020. PMID: 33796864 Free PMC article. - Inherited genetic variants associated with glucocorticoid sensitivity in leukaemia cells.
Shinohara T, Urayama KY, Watanabe A, Akahane K, Goi K, Huang M, Kagami K, Abe M, Sugita K, Okada Y, Goto H, Minegishi M, Iwamoto S, Inukai T. Shinohara T, et al. J Cell Mol Med. 2020 Nov;24(22):12920-12932. doi: 10.1111/jcmm.15882. Epub 2020 Oct 1. J Cell Mol Med. 2020. PMID: 33002292 Free PMC article. - Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
Tomoyasu C, Imamura T, Tomii T, Yano M, Asai D, Goto H, Shimada A, Sanada M, Iwamoto S, Takita J, Minegishi M, Inukai T, Sugita K, Hosoi H. Tomoyasu C, et al. Int J Hematol. 2018 Sep;108(3):312-318. doi: 10.1007/s12185-018-2474-7. Epub 2018 May 21. Int J Hematol. 2018. PMID: 29786757 - Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Takahashi K, Inukai T, Imamura T, Yano M, Tomoyasu C, Lucas DM, Nemoto A, Sato H, Huang M, Abe M, Kagami K, Shinohara T, Watanabe A, Somazu S, Oshiro H, Akahane K, Goi K, Kikuchi J, Furukawa Y, Goto H, Minegishi M, Iwamoto S, Sugita K. Takahashi K, et al. PLoS One. 2017 Dec 13;12(12):e0188680. doi: 10.1371/journal.pone.0188680. eCollection 2017. PLoS One. 2017. PMID: 29236701 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous